Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

When looking ahead to 2025, Cramer noted a significant lack of consensus about future rate cuts. He pointed to Fed funds ...